Video

Efficacy of Sacituzumab Govitecan (SG) in Locally Advanced (LA) or Metastatic Urothelial Cancer (mUC) by Trophoblast Cell Surface Antigen 2 (Trop-2) Expression

Author(s):

Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College

In Partnership With:

Expert Scott Tagawa, MD, MS, FASCO, FACP, reviews recent clinical trial data on UGT1A1- and Trop-2–guided treatment of metastatic urothelial carcinoma.

Related Videos
Phase 3 AMPLIFY Trial
RLY-2608
Rohan Garje, MD
BOVen
John K. Lee, MD, PhD, associate professor-in-residence, Division of Hematology/Oncology, Department of Medicine; the Institute for Urologic Oncology, Department of Urology, the David Geffen School of Medicine, UCLA Heath
RMC-6236
LTE-1 ASPEN LTFU
Data from an Ongoing Phase 1/1b Study BGB-11417-101
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Related Content
Urothelial Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 27th 2025

Nogapendekin Alfa Inbakicept Is Under EMA Review for BCG-Unresponsive NMIBC With CIS

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Urothelial Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 15th 2025

FDA Approval Is Sought for TAR-200 in BCG-Unresponsive High-Risk NMIBC With CIS

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Neal Shore, MD, FACS
January 14th 2025

Sasanlimab Plus BCG Could Alter Treatment Paradigm in BCG-Naive, High-Risk NMIBC

Cancer | Image Credit: © Cornflakesei - stock.adobe.com
January 10th 2025

Sasanlimab Plus BCG Meets EFS End Point in BCG-Naive, High-Risk NMIBC